Interactions Between MiRNAs and Double-Strand Breaks DNA Repair Genes, Pursuing a Fine-Tuning of Repair
Overview
Chemistry
Molecular Biology
Affiliations
The repair of DNA damage is a crucial process for the correct maintenance of genetic information, thus, allowing the proper functioning of cells. Among the different types of lesions occurring in DNA, double-strand breaks (DSBs) are considered the most harmful type of lesion, which can result in significant loss of genetic information, leading to diseases, such as cancer. DSB repair occurs through two main mechanisms, called non-homologous end joining (NHEJ) and homologous recombination repair (HRR). There is evidence showing that miRNAs play an important role in the regulation of genes acting in NHEJ and HRR mechanisms, either through direct complementary binding to mRNA targets, thus, repressing translation, or by targeting other genes involved in the transcription and activity of DSB repair genes. Therefore, alteration of miRNA expression has an impact on the ability of cells to repair DSBs, which, in turn, affects cancer therapy sensitivity. This latter gives account of the importance of miRNAs as regulators of NHEJ and HRR and places them as a promising target to improve cancer therapy. Here, we review recent reports demonstrating an association between miRNAs and genes involved in NHEJ and HRR. We employed the Web of Science search query TS ("gene official symbol/gene aliases*" AND "miRNA/microRNA/miR-") and focused on articles published in the last decade, between 2010 and 2021. We also performed a data analysis to represent miRNA-mRNA validated interactions from TarBase v.8, in order to offer an updated overview about the role of miRNAs as regulators of DSB repair.
Adaptive Significance of Non-coding RNAs: Insights from Cancer Biology.
McDonald J Mol Biol Evol. 2025; 42(1).
PMID: 39761690 PMC: 11725524. DOI: 10.1093/molbev/msae269.
Space radiation damage rescued by inhibition of key spaceflight associated miRNAs.
McDonald J, Kim J, Farmerie L, Johnson M, Trovao N, Arif S Nat Commun. 2024; 15(1):4825.
PMID: 38862542 PMC: 11166944. DOI: 10.1038/s41467-024-48920-y.
Drug resistance in ovarian cancer: from mechanism to clinical trial.
Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y Mol Cancer. 2024; 23(1):66.
PMID: 38539161 PMC: 10976737. DOI: 10.1186/s12943-024-01967-3.
Xie C, Chen X, Chen Y, Wang X, Zuo J, Zheng A Cell Death Dis. 2023; 14(12):846.
PMID: 38114473 PMC: 10730729. DOI: 10.1038/s41419-023-06307-9.
TATDN2 resolution of R-loops is required for survival of BRCA1-mutant cancer cells.
Jaiswal A, Dutta A, Srinivasan G, Yuan Y, Zhou D, Shaheen M Nucleic Acids Res. 2023; 51(22):12224-12241.
PMID: 37953292 PMC: 10711561. DOI: 10.1093/nar/gkad952.